Idenix Pharmaceuticals, Inc.

Summit Corporation Plc

Centre National De La Recherche Scientifique

Novartis Ag

Summit Therapeutics Plc

Novartis Pharma Ag

L'université Montpellier Ii

University of Cagliari

L'universite Montpelier Ii

Universitè De Montpellier

Centre National De La Recherche Scientifique-Cnrs

Universitá Degli Studi Di Cagliari

Richard Storer

Adel M Moussa

Peter David Johnson

Graham Michael Wynne

Colin Richard Dorgan

Olivier De Moor

Cyril B Dousson

Francois-Rene Alexandre

Gilles J Gosselin

Francis Xavier Wilson

Alan Geoffrey Roach

Paul James Davis

Jing Yang Wang

Jean-Pierre Sommadossi

David Dukhan

David Thomas Jonaitis

Benjamin Alexander Mayes

Frederic Leroy

Alistair James Stewart

David T Jonaitis

Stephen Paul Wren

Richard Vickers

Edward Bridges

Richard Joseph Pye

Arlene Roland

Gary Nugent

Paul Damien Price

Paolo LaColla

Marino Artico

Paolo La Colla

Frank Walter Waligora

Richard John Vickers

Arlène Roland

Romano Silvestri

Narayan Chaudhuri

Jonathon Mark Tinsley

Francois-René Alexandre

David Jonaitis

Poalo La Colla

Frank Waligora

Dousson Cyril

Frédéric Leroy

Disclosed are compounds of formula (I): which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by,

Antibacterial compounds

This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine. The optionally substituted pentofuranonucleoside, or a salt or prodrug thereof, may be administered alone or in combination with one or more optionally substituted pentofuranonucleosides or other anti-viral agents.

Purine nucleoside analogues for treating flaviviridae including hepatitis C

Disclosed are compounds of formula (I), which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by,. 

[object Object]

2' and/or 3&#x2032; prodrugs of 1&#x2032;, 2&#x2032;, 3&#x2032; or 4&#x2032;-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.

Modified 2' and 3&#x2032; nucleoside prodrugs for treating flaviviridae infections

There are disclosed compound of Formula (1): A, A, Aand Awhich may be the same or different, represent N or CR, X is a divalent group selected from O, S(O), C&#x2550;W, NR, NC(&#x2550;O)Rand CRR, W is O, S, NR, Y is N or CR, one of R, R, R, R, Rand NRrepresents -L-R, in which L is a single bond or a linker group, additionally, R, R-R, which may be the same or different, independently represent hydrogen or a substituent and Rrepresents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO, NRR, in which Rand R, which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of Rand Rmay represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent pair of A-Aeach represent CR, then the adjacent carbon atoms, together with their substituents may form a ring B, when X is CRR, Rand R, together with the carbon atom to which they are attached may form a ring C, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia. 

Treatment of Duchenne muscular dystrophy

Combinations comprising (or consisting essentially of) one or more compounds of formula (1) with one or more ancillary agents, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations. 

Drug combinations for the treatment of duchenne muscular dystrophy

3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of Flaviviridae virus infections, and particularly for HIV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other anti-viral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.

Enantiomerically pure phosphoindoles as HIV inhibitors

3-phosphoindole compounds for the treatment of retroviral infections, and particularly for HIV, are described. Also included are compositions comprising the 3-phosphoindole derivatives alone or in combination with one or more other anti-retroviral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.

Phospho-indoles as HIV inhibitors

Physical forms of beta-L-2'-deoxythymidine are disclosed that can be characterized by physical appearance, purity levels, Infra-Red and Raman spectroscopy, X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These forms of beta-L-2&#x2032;-deoxythymidine can be used in the manufacture of other forms of beta-L-2&#x2032;-deoxythymidine, or in pharmaceutical compositions. Particularly preferred uses are in the treatment of hepatitis B.

Crystalline and amorphous forms of beta-L-2'-deoxythymidine

The present invention provides an improved process for preparing 2-C-methyl-D-ribonolactone.

Process for the production of 2-C-methyl-D-ribonolactone

An industrially scalable two-step process for preparing a &#x3b2;-L-2'-deoxy-nucleoside that results in a predominance of the &#x3b2;- over the &#x3b1;-anomeric form of the compound is described. An optional third step may be used to prepare 3&#x2032;-prodrugs of desirable &#x3b2;-L-2&#x2032;-deoxy-nucleosides for the delivery of these pharmaceuticals effective for treating viral diseases. The synthetic process is applicable in particular to the formation of &#x3b2;-L-2&#x2032;-deoxy-cytidine, a pharmaceutically acceptable salt or prodrug thereof. The process can provide a relatively uncontaminated product that may require no further isolation or purification, thereby making the synthesis easily scalable for industrial manufacture.

Industrially scalable nucleoside synthesis

Growing community of inventors

Folkestone, United Kingdom

Richard Storer